MA40228A - Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser - Google Patents
Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliserInfo
- Publication number
- MA40228A MA40228A MA040228A MA40228A MA40228A MA 40228 A MA40228 A MA 40228A MA 040228 A MA040228 A MA 040228A MA 40228 A MA40228 A MA 40228A MA 40228 A MA40228 A MA 40228A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- recombinant listeria
- fusion proteins
- heterologous antigen
- listeria strain
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/01—Racemaces and epimerases (5.1) acting on amino acids and derivatives (5.1.1)
- C12Y501/01001—Alanine racemase (5.1.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/55—Vectors comprising a special origin of replication system from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des acides nucléiques recombinés codant pour des antigènes tumoraux fusionnés à des polypeptides immunogènes et des souches de listéria recombinées les comprenant, des procédés pour les préparer, et des procédés pour induire une réponse immunitaire, et pour traiter, inhiber ou supprimer un cancer ou des tumeurs comprenant l'administration de celles-ci.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026085P | 2014-07-18 | 2014-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40228A true MA40228A (fr) | 2017-05-24 |
Family
ID=55079085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040228A MA40228A (fr) | 2014-07-18 | 2015-07-17 | Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170246273A1 (fr) |
EP (1) | EP3169356A4 (fr) |
JP (1) | JP2017522027A (fr) |
KR (1) | KR20170028363A (fr) |
CN (1) | CN107073094A (fr) |
AU (1) | AU2015289529A1 (fr) |
CA (1) | CA2955366A1 (fr) |
IL (1) | IL249903A0 (fr) |
MA (1) | MA40228A (fr) |
MX (1) | MX2017000838A (fr) |
SG (1) | SG11201700092XA (fr) |
WO (1) | WO2016011353A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
CA2829960A1 (fr) | 2011-03-11 | 2012-09-20 | John Rothman | Adjuvants a base de listeria |
JP2015511602A (ja) | 2012-03-12 | 2015-04-20 | アドバクシス, インコーポレイテッド | リステリアワクチン処理後のサプレッサー細胞機能抑制 |
CN106456726A (zh) | 2014-02-18 | 2017-02-22 | 阿德瓦希斯公司 | 生物标志物导向的多靶点免疫治疗 |
EP3134510B1 (fr) | 2014-04-24 | 2023-11-01 | Advaxis, Inc. | Souches de listeria utilisées comme vaccin recombinant et procédé de production |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
SG11201901979SA (en) | 2016-11-30 | 2019-04-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
US10372132B2 (en) | 2016-12-12 | 2019-08-06 | Apple Inc. | Guidance of autonomous vehicles in destination vicinities using intent signals |
AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
JP2021502083A (ja) * | 2017-11-08 | 2021-01-28 | アドバクシス, インコーポレイテッド | がん関連タンパク質由来の免疫原性ヘテロクリティックペプチドおよびその使用の方法 |
WO2019157098A1 (fr) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprenant une souche de listeria recombinante et un anticorps anti-ccr8 et méthodes d'utilisation |
CA3093467C (fr) * | 2018-03-09 | 2022-12-06 | Advaxis, Inc. | Compositions et methodes d'evaluation d'attenuation et d'infectivite de souches de listeria |
SG10201901828TA (en) * | 2019-02-28 | 2020-09-29 | Nat Univ Singapore | Recombinant bacteria and uses thereof |
CN110607267B (zh) * | 2019-09-25 | 2021-06-22 | 四川大学 | 一种绵羊李斯特菌平衡致死系统、构建方法及应用 |
CN114561417B (zh) * | 2022-04-27 | 2022-08-09 | 中国科学院天津工业生物技术研究所 | 用于制备阿洛酮糖的谷氨酸棒杆菌工程菌株及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100424096C (zh) * | 2005-06-16 | 2008-10-08 | 华东理工大学 | 含有hiv转导结构域的生存素突变体及制备方法和应用 |
US20120135033A1 (en) * | 2008-05-19 | 2012-05-31 | Anu Wallecha | Multiple delivery system for heterologous antigens |
ES2741730T3 (es) * | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
WO2011100754A1 (fr) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central |
CA2829960A1 (fr) * | 2011-03-11 | 2012-09-20 | John Rothman | Adjuvants a base de listeria |
WO2016154412A2 (fr) * | 2015-03-26 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement d'un cancer du pancréas |
-
2015
- 2015-07-17 CN CN201580039780.3A patent/CN107073094A/zh active Pending
- 2015-07-17 SG SG11201700092XA patent/SG11201700092XA/en unknown
- 2015-07-17 JP JP2017502680A patent/JP2017522027A/ja active Pending
- 2015-07-17 US US15/325,955 patent/US20170246273A1/en not_active Abandoned
- 2015-07-17 KR KR1020177001578A patent/KR20170028363A/ko unknown
- 2015-07-17 MX MX2017000838A patent/MX2017000838A/es unknown
- 2015-07-17 WO PCT/US2015/040911 patent/WO2016011353A1/fr active Application Filing
- 2015-07-17 EP EP15822487.3A patent/EP3169356A4/fr not_active Withdrawn
- 2015-07-17 MA MA040228A patent/MA40228A/fr unknown
- 2015-07-17 CA CA2955366A patent/CA2955366A1/fr not_active Abandoned
- 2015-07-17 AU AU2015289529A patent/AU2015289529A1/en not_active Abandoned
-
2017
- 2017-01-02 IL IL249903A patent/IL249903A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN107073094A (zh) | 2017-08-18 |
JP2017522027A (ja) | 2017-08-10 |
EP3169356A4 (fr) | 2018-03-28 |
MX2017000838A (es) | 2017-09-01 |
CA2955366A1 (fr) | 2016-01-21 |
KR20170028363A (ko) | 2017-03-13 |
SG11201700092XA (en) | 2017-02-27 |
EP3169356A1 (fr) | 2017-05-24 |
WO2016011353A1 (fr) | 2016-01-21 |
AU2015289529A1 (en) | 2017-02-09 |
IL249903A0 (en) | 2017-03-30 |
US20170246273A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017000838A (es) | Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas. | |
MA39849A (fr) | Souches de listeria utilisées comme vaccin recombinant et procédé de production | |
MX2017008187A (es) | Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr. | |
MX2017000836A (es) | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. | |
MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2016010565A (es) | Inmunoterapia del cancer a través de la combinacion de estimulacion inmunatoria local y sistemica. | |
MX2019003445A (es) | Proteinas de fusion inmunomoduladoras. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
MY193497A (en) | Anti-myostatin antibodies and methods of use | |
MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
PH12019500591A1 (en) | Canine adenovirus vectors | |
MX2020004829A (es) | Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos. | |
MX2014009845A (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
MX2022007902A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
IL258004A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
AR110730A1 (es) | Vacunas de cepas recombinantes de listeria y método para usarlas en inmunoterapia de cáncer | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
WO2019006401A3 (fr) | Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants | |
NZ742663A (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
HK1248610A1 (zh) | 包含經修飾的α病毒表面糖蛋白與腫瘤相關抗原的融合蛋白及其方法 | |
NZ743236A (en) | Fmdv and e2 fusion proteins and uses thereof |